CXCL2 and hepatocellular carcinoma: As shown in Figure 3A–D, higher expression of CXCL10 was associated with better DSS (HR = 0.63, P=0.042); overexpression of CXCL2 was associated with longer PFS and DSS (PFS: HR = 0.74, P=0.046; DDS: HR = 0.67, P=0.016); up-expression of CXCL12 was related to favorable RFS and PFS (RFS: HR = 0.65, P=0.0097; PFS: HR = 0.68, P=0.01); and up-regulation of CXCL14 was linked to better RFS (HR = 0.65, P=0.011) of HCC patients.